Montano CB, Patel M, Jain R, Masand PS, Harrington A, Gillard P, Sullivan K, McElroy SL, Brown TM, Nelson L, McIntyre RS. The rapid mood screener: a novel and pragmatic screener tool for bipolar I disorder. CNS Spectr. 2021 Apr;26(2):167-8. doi: 10.1017/S1092852920002709
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Fehnel SE, Forsyth BH, DiBenedetti DB, Danchenko N, Francios C, Brevig T. Patient-centered assessment of cognitive symptoms of depression. CNS Spectr. 2016 Feb;21(1):43-52. doi: 10.1017/S1092852913000643
White MV, Silvia S, Hollis K, Wooddell M, Hogue S. Differences in anaphylaxis-related risks by school grade level: findings from the EpiPen4Schools® survey. Poster presented at the 2015 ASCIA Conference; September 2015. Adelaide, Australia. [abstract] Intern Med J. 2015 Sep 3; 45(Suppl 4):3. doi: 10.1111/imj.12869
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.